Tags

Type your tag names separated by a space and hit enter

Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern.
Clin Microbiol Infect. 2022 Jun; 28(6):882.e1-882.e7.CM

Abstract

OBJECTIVES

The BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against variants of concern. We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants to neutralizing antibodies (NAbs) present in sera from individuals who had received the BIV1-CovIran candidate vaccine compared with an original Wuhan-related strain.

METHODS

The ability of vaccine serum to neutralize the variants was measured using the conventional virus neutralization test. The correlation of spike (S) protein antibody and anti-receptor binding domain with neutralizing activity was investigated.

RESULTS

The current study demonstrated that 29 of 32 (90.6%; 95% CI: 75.0-98.0) of the vaccinees developed NAbs against a Wuhan-related strain. It is noteworthy that 28 (87.50%) and 24 of 32 (75%) of the recipients were able to produce NAbs against Alpha, Beta, and Delta variants, respectively. Serum virus-neutralizing titres for different SARS-CoV-2 strains were weakly correlated with anti-receptor binding domain antibodies (Spearman r = 36-42, p < 0.05), but not S-binding antibodies (p > 0.05).

DISCUSSION

Although there was a reduction in neutralization titres against the Alpha, Beta, and Delta variants compared with the Wuhan strain, BIV1-CovIran still exhibited potent neutralizing activity against the SARS-CoV-2 variants of concern.

Links

PMC Free PDF

Authors+Show Affiliations

Salehi M
Infectious Diseases Department, Tehran University of Medical Sciences, Tehran, Iran.
Hosseini H
Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Jamshidi HR
Department of Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jalili H
Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
Tabarsi P
Department of Infectious Disease, Clinical Tuberculosis and Epidemiology Research Center, Shahid Beheshti University of Medical Sciences Tehran, Iran.
Mohraz M
Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences Tehran, Iran.
Karimi H
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Lotfinia M
Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Aalizadeh R
Department of Biochemistry, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran.
Mohammadi M
Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Ramazi S
Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Abdoli A
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran; Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran. Electronic address: asghar.abdoli7@gmail.com.

MeSH

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesHumansSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, Inactivated

Pub Type(s)

Journal Article

Language

eng

PubMed ID

35248745

Citation

Salehi, Mohammadreza, et al. "Assessment of BIV1-CovIran Inactivated Vaccine-elicited Neutralizing Antibody Against the Emerging SARS-CoV-2 Variants of Concern." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 28, no. 6, 2022, pp. 882.e1-882.e7.
Salehi M, Hosseini H, Jamshidi HR, et al. Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern. Clin Microbiol Infect. 2022;28(6):882.e1-882.e7.
Salehi, M., Hosseini, H., Jamshidi, H. R., Jalili, H., Tabarsi, P., Mohraz, M., Karimi, H., Lotfinia, M., Aalizadeh, R., Mohammadi, M., Ramazi, S., & Abdoli, A. (2022). Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 28(6), e1-e7. https://doi.org/10.1016/j.cmi.2022.02.030
Salehi M, et al. Assessment of BIV1-CovIran Inactivated Vaccine-elicited Neutralizing Antibody Against the Emerging SARS-CoV-2 Variants of Concern. Clin Microbiol Infect. 2022;28(6):882.e1-882.e7. PubMed PMID: 35248745.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern. AU - Salehi,Mohammadreza, AU - Hosseini,Hamed, AU - Jamshidi,Hamid Reza, AU - Jalili,Hasan, AU - Tabarsi,Payam, AU - Mohraz,Minoo, AU - Karimi,Hesam, AU - Lotfinia,Majid, AU - Aalizadeh,Reza, AU - Mohammadi,Mehrdad, AU - Ramazi,Shahin, AU - Abdoli,Asghar, Y1 - 2022/03/03/ PY - 2021/12/17/received PY - 2022/02/09/revised PY - 2022/02/19/accepted PY - 2022/3/7/pubmed PY - 2022/5/27/medline PY - 2022/3/6/entrez KW - BIV1-CovIran vaccine KW - COVID-19 vaccine KW - SARS-CoV-2 variants KW - Virus neutralization test SP - 882.e1 EP - 882.e7 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin Microbiol Infect VL - 28 IS - 6 N2 - OBJECTIVES: The BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against variants of concern. We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants to neutralizing antibodies (NAbs) present in sera from individuals who had received the BIV1-CovIran candidate vaccine compared with an original Wuhan-related strain. METHODS: The ability of vaccine serum to neutralize the variants was measured using the conventional virus neutralization test. The correlation of spike (S) protein antibody and anti-receptor binding domain with neutralizing activity was investigated. RESULTS: The current study demonstrated that 29 of 32 (90.6%; 95% CI: 75.0-98.0) of the vaccinees developed NAbs against a Wuhan-related strain. It is noteworthy that 28 (87.50%) and 24 of 32 (75%) of the recipients were able to produce NAbs against Alpha, Beta, and Delta variants, respectively. Serum virus-neutralizing titres for different SARS-CoV-2 strains were weakly correlated with anti-receptor binding domain antibodies (Spearman r = 36-42, p < 0.05), but not S-binding antibodies (p > 0.05). DISCUSSION: Although there was a reduction in neutralization titres against the Alpha, Beta, and Delta variants compared with the Wuhan strain, BIV1-CovIran still exhibited potent neutralizing activity against the SARS-CoV-2 variants of concern. SN - 1469-0691 UR - https://www.unboundmedicine.com/medline/citation/35248745/Assessment_of_BIV1_CovIran_inactivated_vaccine_elicited_neutralizing_antibody_against_the_emerging_SARS_CoV_2_variants_of_concern_ DB - PRIME DP - Unbound Medicine ER -